Wesbanco Bank Inc. Increases Stake in Amgen Inc. $AMGN

Wesbanco Bank Inc. lifted its position in Amgen Inc. (NASDAQ:AMGN) by 4.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,808 shares of the medical research company’s stock after acquiring an additional 2,684 shares during the period. Wesbanco Bank Inc.’s holdings in Amgen were worth $19,700,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Legacy Investment Solutions LLC bought a new stake in shares of Amgen during the 2nd quarter valued at about $27,000. Evelyn Partners Investment Management LLP bought a new position in shares of Amgen in the 2nd quarter worth approximately $32,000. Howard Hughes Medical Institute purchased a new position in shares of Amgen in the second quarter worth approximately $32,000. Quaker Wealth Management LLC grew its position in Amgen by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after buying an additional 240 shares during the period. Finally, Cloud Capital Management LLC purchased a new stake in Amgen during the third quarter valued at approximately $34,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent research reports. Piper Sandler increased their price target on shares of Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Royal Bank Of Canada raised their target price on Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. UBS Group lifted their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Finally, Morgan Stanley raised their price objective on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $351.65.

Amgen Stock Down 2.2%

Shares of AMGN opened at $375.82 on Tuesday. The business’s 50 day moving average is $335.21 and its 200 day moving average is $311.98. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $385.12. The company has a market capitalization of $202.37 billion, a PE ratio of 26.41, a price-to-earnings-growth ratio of 3.96 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s dividend payout ratio is 66.90%.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 890 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.